EE346 Comparison of Diagnosis, Administration, and Treatment-Related Cost of Targeted Radiopharmaceutical Therapies in Patients With Metastatic Castration-Resistant Prostate Cancer (MCRPC) From a Third-Party Payer Perspective
Dec 1, 2022, 00:00 AM
10.1016/j.jval.2022.09.592
https://www.valueinhealthjournal.com/article/S1098-3015(22)02796-6/fulltext
Section Title :
Section Order :
10124
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02796-6&doi=10.1016/j.jval.2022.09.592